These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28131423)

  • 41. Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies.
    Kunutsor SK; Blom AW; Whitehouse MR; Kehoe PG; Laukkanen JA
    Eur J Epidemiol; 2017 Nov; 32(11):947-959. PubMed ID: 28752198
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Angiotensin-Converting Enzyme Inhibitor-based Versus Angiotensin Receptor Blocker-based Optimal Medical Therapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study.
    Park S; Kim YG; Ann SH; Park HW; Suh J; Roh JH; Cho YR; Han S; Park GM
    J Cardiovasc Pharmacol; 2021 Jan; 77(1):61-68. PubMed ID: 33165139
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease.
    Lebek S; Tafelmeier M; Messmann R; Provaznik Z; Schmid C; Maier LS; Birner C; Arzt M; Wagner S
    Eur J Heart Fail; 2020 Dec; 22(12):2248-2257. PubMed ID: 33017071
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment with renin-angiotensin system inhibitors and prognosis of heart failure with preserved ejection fraction: A propensity-matched study in the community.
    Egido JJ; Gomez R; Romero SP; Andrey JL; Ramirez D; Rodriguez A; Pedrosa MJ; Gomez F
    Int J Clin Pract; 2019 Jun; 73(6):e13317. PubMed ID: 30694579
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary prevention of myocardial infarction with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients with rheumatoid arthritis-A nationwide cohort study.
    Lin TT; Wu CK; Liao MT; Yang YH; Chen PC; Yeih DF; Lin LY
    PLoS One; 2017; 12(12):e0188720. PubMed ID: 29216228
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study.
    Ferreira JP; Couchoud C; Gregson J; Tiple A; Glowacki F; London G; Agarwal R; Rossignol P
    Nephrol Dial Transplant; 2019 Jul; 34(7):1216-1222. PubMed ID: 30590716
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
    Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
    BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia.
    Armstrong EJ; Chen DC; Singh GD; Amsterdam EA; Laird JR
    Vasc Med; 2015 Jun; 20(3):237-44. PubMed ID: 25835349
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study).
    AlJaroudi WA; Refaat MM; Habib RH; Al-Shaar L; Singh M; Gutmann R; Bloom HL; Dudley SC; Ellinor PT; Saba SF; Shalaby AA; Weiss R; McNamara DM; Halder I; London B;
    Am J Cardiol; 2015 Apr; 115(7):924-31. PubMed ID: 25682436
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
    Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
    Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID-19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System.
    An J; Wei R; Zhou H; Luong TQ; Gould MK; Mefford MT; Harrison TN; Creekmur B; Lee MS; Sim JJ; Brettler JW; Martin JP; Ong-Su AL; Reynolds K
    J Am Heart Assoc; 2021 Feb; 10(3):e019669. PubMed ID: 33307964
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Incidence and Risk of Biochemical Recurrence Following Radical Radiotherapy for Prostate Cancer in Men on Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin Receptor Blockers (ARBs).
    Alashkham A; Paterson C; Windsor P; Struthers A; Rauchhaus P; Nabi G
    Clin Genitourin Cancer; 2016 Oct; 14(5):398-405. PubMed ID: 27053500
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patterns of use of perioperative angiotensin-converting enzyme inhibitors in coronary artery bypass graft surgery with cardiopulmonary bypass: effects on in-hospital morbidity and mortality.
    Drenger B; Fontes ML; Miao Y; Mathew JP; Gozal Y; Aronson S; Dietzel C; Mangano DT; ;
    Circulation; 2012 Jul; 126(3):261-9. PubMed ID: 22715473
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improved survival with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic limb-threatening ischemia.
    Khan SZ; O'Brien-Irr MS; Rivero M; Blochle R; Cherr GS; Dryjski ML; Dosluoglu HH; Lukan J; Rowe VL; Harris LM
    J Vasc Surg; 2020 Dec; 72(6):2130-2138. PubMed ID: 32276021
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of cardiocerebrovascular disease incidence between angiotensin converting enzyme inhibitor and angiotensin receptor blocker users in a real-world cohort.
    Lee S; Kim H; Woo Yim H; Hun-Sung K; Han Kim J
    J Appl Biomed; 2023 Apr; 21(1):7-14. PubMed ID: 37016775
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
    Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
    Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of preoperative angiotensin-converting enzyme inhibitor on the outcome of coronary artery bypass graft surgery.
    Zhang Y; Ma L
    Eur J Cardiothorac Surg; 2015 May; 47(5):788-95. PubMed ID: 25079771
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials.
    Hoang V; Alam M; Addison D; Macedo F; Virani S; Birnbaum Y
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):189-98. PubMed ID: 26861251
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients.
    Trifirò G; Massari M; Da Cas R; Menniti Ippolito F; Sultana J; Crisafulli S; Giorgi Rossi P; Marino M; Zorzi M; Bovo E; Leoni O; Ludergnani M; Spila Alegiani S;
    Drug Saf; 2020 Dec; 43(12):1297-1308. PubMed ID: 32852721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.